LDE Stock Chart & Stats
€3.80
€0.04(1.08%)
At close: 4:00 PM EDT
€3.80
€0.04(1.08%)
Day’s Range― - ―
52-Week Range€3.12 - €7.30
Previous CloseN/A
Volume0.00
Average Volume (3M)61.00
Market Cap
€221.93M
Enterprise Value€386.59
Total Cash (Recent Filing)€17.47M
Total Debt (Recent Filing)€142.61M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
May 12, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding37,905,846
10 Day Avg. Volume184
30 Day Avg. Volume61
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)-19.16
Price to Sales (P/S)2.10
P/FCF Ratio43.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.54Price Target Upside45.89% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.93
Revenue Forecast (FY)€106.91M
Bulls Say, Bears Say
Bulls Say
Specialized CDMO PlatformLifecore’s specialized sterile fill-finish platform addresses complex manufacturing needs for injectable biologics and supports customers across development, production, and quality services. This breadth can deepen customer relationships and create durable value as programs advance toward commercialization.
Long-Term Alcon ContractThe extended Alcon term and contractual purchase commitments improve multi-year revenue visibility and provide a foundation for steadier capacity utilization. A deeper relationship with a major customer may also strengthen Lifecore’s credibility and positioning within specialized manufacturing.
Improved 2026 Cash GenerationPositive operating and free cash flow in 2026 indicates that Lifecore generated cash from its business after several weaker years. If maintained, this improvement could support operations, reduce reliance on external funding, and help finance required investment in manufacturing capabilities.
Bears Say
Highly Leveraged Balance SheetHigh debt relative to the asset base and negative stockholders’ equity materially reduce financial flexibility. This structure can constrain investment and increase refinancing or solvency pressure, making the company more exposed if operating performance weakens or funding conditions become less favorable.
Persistent Unprofitable OperationsLifecore has not converted its CDMO activity into consistent profitability: revenue is broadly flat, operating losses continue, and a large 2026 net loss followed a reversal from positive earnings in 2024. This volatility limits internally generated capital and weakens earnings visibility.
Inconsistent Cash Flow QualityAlthough 2026 cash generation improved, the multi-year pattern remains uneven and free cash flow declined substantially from the prior year. Such inconsistency makes it harder to depend on operations for debt service, expansion spending, and other long-term capital requirements.
Lifecore Biomedical News
LDE FAQ
What was Lifecore Biomedical’s price range in the past 12 months?
Lifecore Biomedical lowest stock price was €3.12 and its highest was €7.30 in the past 12 months.
What is Lifecore Biomedical’s market cap?
Lifecore Biomedical’s market cap is €221.93M.
When is Lifecore Biomedical’s upcoming earnings report date?
Lifecore Biomedical’s upcoming earnings report date is May 12, 2027 which is in 221 days.
How were Lifecore Biomedical’s earnings last quarter?
Lifecore Biomedical released its earnings results on Aug 05, 2026. The company reported -€0.169 earnings per share for the quarter, beating the consensus estimate of -€0.197 by €0.028.
Is Lifecore Biomedical overvalued?
According to Wall Street analysts Lifecore Biomedical’s price is currently Undervalued.
Does Lifecore Biomedical pay dividends?
Lifecore Biomedical does not currently pay dividends.
What is Lifecore Biomedical’s EPS estimate?
Lifecore Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lifecore Biomedical have?
Lifecore Biomedical has 37,905,846 shares outstanding.
What happened to Lifecore Biomedical’s price movement after its last earnings report?
Lifecore Biomedical reported an EPS of -€0.169 in its last earnings report, beating expectations of -€0.197. Following the earnings report the stock price went up 1.63%.
Which hedge fund is a major shareholder of Lifecore Biomedical?
Currently, no hedge funds are holding shares in DE:LDE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lifecore Biomedical Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Lifecore Biomedical
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
LDE Company Deck
LDE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced/Neutral. The call highlighted substantial strategic and operational progress — a growing late-stage pipeline, meaningful new business momentum (13 wins in 12 months), successful regulatory audits (including PMDA), sustained SG&A reductions (cumulative $16.2M) and improved liquidity ($38.8M) — and management reaffirmed 2026 guidance. However, near-term financials showed meaningful declines: Q2 revenue down 6.2% YoY and six-month revenue down 19.9%, widened net losses (Q2 and 6-month), and a sizable drop in 6-month adjusted EBITDA (~34.5%). Management expects a back-half recovery and a 2027–2028 volume inflection with a major customer's committed demand ramp, but execution and timing risks remain. Overall, positives around pipeline, wins, quality and cost discipline are offset by short-term revenue and profitability headwinds, yielding a neutral outlook.View all DE:LDE earnings summariesLDE Stock 12 Month Forecast
Average Price Target
€5.54
▲(45.89% Upside)
Technical Analysis
Ironwood Pharma
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―